Leading antibacterial laboratory research by integrating conventional and innovative approaches

The Laboratory Center of the Antibacterial Resistance Leadership Group

Claudia Manca, Carol Hill, Andrea M. Hujer, Robin Patel, Scott R. Evans, Robert A. Bonomo, Barry N. Kreiswirth

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The Antibacterial Resistance Leadership Group (ARLG) Laboratory Center (LC) leads the evaluation, development, and implementation of laboratory-based research by providing scientific leadership and supporting standard/specialized laboratory services. The LC has developed a physical biorepository and a virtual biorepository. The physical biorepository contains bacterial isolates from ARLG-funded studies located in a centralized laboratory and they are available to ARLG investigators. The Web-based virtual biorepository strain catalogue includes well-characterized gram-positive and gram-negative bacterial strains published by ARLG investigators. The LC, in collaboration with the ARLG Leadership and Operations Center, developed procedures for review and approval of strain requests, guidance during the selection process, and for shipping strains from the distributing laboratories to the requesting investigators. ARLG strains and scientific and/or technical guidance have been provided to basic research laboratories and diagnostic companies for research and development, facilitating collaboration between diagnostic companies and the ARLG Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND) initiative for evaluation of multiple diagnostic devices from a single patient sampling event. In addition, the LC has completed several laboratory-based studies designed to help evaluate new rapid molecular diagnostics by developing, testing, and applying a MASTERMIND approach using purified bacterial strains. In collaboration with the ARLG's Statistical and Data Management Center (SDMC), the LC has developed novel analytical strategies that integrate microbiologic and genetic data for improved and accurate identification of antimicrobial resistance. These novel approaches will aid in the design of future ARLG studies and help correlate pathogenic markers with clinical outcomes. The LC's accomplishments are the result of a successful collaboration with the ARLG's Leadership and Operations Center, Diagnostics and Devices Committee, and SDMC. This interactive approach has been pivotal for the success of LC projects.

Original languageEnglish (US)
Pages (from-to)S13-S17
JournalClinical Infectious Diseases
Volume64
DOIs
StatePublished - 2017

Fingerprint

Research
Research Personnel
Molecular Diagnostic Techniques
Equipment and Supplies
Infection
Biomarkers

Keywords

  • Antibacterial Resistance
  • Bacterial strains
  • Biorepository
  • Diagnostics and Devices
  • Drug testing

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Leading antibacterial laboratory research by integrating conventional and innovative approaches : The Laboratory Center of the Antibacterial Resistance Leadership Group. / Manca, Claudia; Hill, Carol; Hujer, Andrea M.; Patel, Robin; Evans, Scott R.; Bonomo, Robert A.; Kreiswirth, Barry N.

In: Clinical Infectious Diseases, Vol. 64, 2017, p. S13-S17.

Research output: Contribution to journalArticle

Manca, Claudia ; Hill, Carol ; Hujer, Andrea M. ; Patel, Robin ; Evans, Scott R. ; Bonomo, Robert A. ; Kreiswirth, Barry N. / Leading antibacterial laboratory research by integrating conventional and innovative approaches : The Laboratory Center of the Antibacterial Resistance Leadership Group. In: Clinical Infectious Diseases. 2017 ; Vol. 64. pp. S13-S17.
@article{ffb72974c19d4cffbe4d5b0a1e30b0aa,
title = "Leading antibacterial laboratory research by integrating conventional and innovative approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group",
abstract = "The Antibacterial Resistance Leadership Group (ARLG) Laboratory Center (LC) leads the evaluation, development, and implementation of laboratory-based research by providing scientific leadership and supporting standard/specialized laboratory services. The LC has developed a physical biorepository and a virtual biorepository. The physical biorepository contains bacterial isolates from ARLG-funded studies located in a centralized laboratory and they are available to ARLG investigators. The Web-based virtual biorepository strain catalogue includes well-characterized gram-positive and gram-negative bacterial strains published by ARLG investigators. The LC, in collaboration with the ARLG Leadership and Operations Center, developed procedures for review and approval of strain requests, guidance during the selection process, and for shipping strains from the distributing laboratories to the requesting investigators. ARLG strains and scientific and/or technical guidance have been provided to basic research laboratories and diagnostic companies for research and development, facilitating collaboration between diagnostic companies and the ARLG Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND) initiative for evaluation of multiple diagnostic devices from a single patient sampling event. In addition, the LC has completed several laboratory-based studies designed to help evaluate new rapid molecular diagnostics by developing, testing, and applying a MASTERMIND approach using purified bacterial strains. In collaboration with the ARLG's Statistical and Data Management Center (SDMC), the LC has developed novel analytical strategies that integrate microbiologic and genetic data for improved and accurate identification of antimicrobial resistance. These novel approaches will aid in the design of future ARLG studies and help correlate pathogenic markers with clinical outcomes. The LC's accomplishments are the result of a successful collaboration with the ARLG's Leadership and Operations Center, Diagnostics and Devices Committee, and SDMC. This interactive approach has been pivotal for the success of LC projects.",
keywords = "Antibacterial Resistance, Bacterial strains, Biorepository, Diagnostics and Devices, Drug testing",
author = "Claudia Manca and Carol Hill and Hujer, {Andrea M.} and Robin Patel and Evans, {Scott R.} and Bonomo, {Robert A.} and Kreiswirth, {Barry N.}",
year = "2017",
doi = "10.1093/cid/ciw826",
language = "English (US)",
volume = "64",
pages = "S13--S17",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Leading antibacterial laboratory research by integrating conventional and innovative approaches

T2 - The Laboratory Center of the Antibacterial Resistance Leadership Group

AU - Manca, Claudia

AU - Hill, Carol

AU - Hujer, Andrea M.

AU - Patel, Robin

AU - Evans, Scott R.

AU - Bonomo, Robert A.

AU - Kreiswirth, Barry N.

PY - 2017

Y1 - 2017

N2 - The Antibacterial Resistance Leadership Group (ARLG) Laboratory Center (LC) leads the evaluation, development, and implementation of laboratory-based research by providing scientific leadership and supporting standard/specialized laboratory services. The LC has developed a physical biorepository and a virtual biorepository. The physical biorepository contains bacterial isolates from ARLG-funded studies located in a centralized laboratory and they are available to ARLG investigators. The Web-based virtual biorepository strain catalogue includes well-characterized gram-positive and gram-negative bacterial strains published by ARLG investigators. The LC, in collaboration with the ARLG Leadership and Operations Center, developed procedures for review and approval of strain requests, guidance during the selection process, and for shipping strains from the distributing laboratories to the requesting investigators. ARLG strains and scientific and/or technical guidance have been provided to basic research laboratories and diagnostic companies for research and development, facilitating collaboration between diagnostic companies and the ARLG Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND) initiative for evaluation of multiple diagnostic devices from a single patient sampling event. In addition, the LC has completed several laboratory-based studies designed to help evaluate new rapid molecular diagnostics by developing, testing, and applying a MASTERMIND approach using purified bacterial strains. In collaboration with the ARLG's Statistical and Data Management Center (SDMC), the LC has developed novel analytical strategies that integrate microbiologic and genetic data for improved and accurate identification of antimicrobial resistance. These novel approaches will aid in the design of future ARLG studies and help correlate pathogenic markers with clinical outcomes. The LC's accomplishments are the result of a successful collaboration with the ARLG's Leadership and Operations Center, Diagnostics and Devices Committee, and SDMC. This interactive approach has been pivotal for the success of LC projects.

AB - The Antibacterial Resistance Leadership Group (ARLG) Laboratory Center (LC) leads the evaluation, development, and implementation of laboratory-based research by providing scientific leadership and supporting standard/specialized laboratory services. The LC has developed a physical biorepository and a virtual biorepository. The physical biorepository contains bacterial isolates from ARLG-funded studies located in a centralized laboratory and they are available to ARLG investigators. The Web-based virtual biorepository strain catalogue includes well-characterized gram-positive and gram-negative bacterial strains published by ARLG investigators. The LC, in collaboration with the ARLG Leadership and Operations Center, developed procedures for review and approval of strain requests, guidance during the selection process, and for shipping strains from the distributing laboratories to the requesting investigators. ARLG strains and scientific and/or technical guidance have been provided to basic research laboratories and diagnostic companies for research and development, facilitating collaboration between diagnostic companies and the ARLG Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND) initiative for evaluation of multiple diagnostic devices from a single patient sampling event. In addition, the LC has completed several laboratory-based studies designed to help evaluate new rapid molecular diagnostics by developing, testing, and applying a MASTERMIND approach using purified bacterial strains. In collaboration with the ARLG's Statistical and Data Management Center (SDMC), the LC has developed novel analytical strategies that integrate microbiologic and genetic data for improved and accurate identification of antimicrobial resistance. These novel approaches will aid in the design of future ARLG studies and help correlate pathogenic markers with clinical outcomes. The LC's accomplishments are the result of a successful collaboration with the ARLG's Leadership and Operations Center, Diagnostics and Devices Committee, and SDMC. This interactive approach has been pivotal for the success of LC projects.

KW - Antibacterial Resistance

KW - Bacterial strains

KW - Biorepository

KW - Diagnostics and Devices

KW - Drug testing

UR - http://www.scopus.com/inward/record.url?scp=85033549722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033549722&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw826

DO - 10.1093/cid/ciw826

M3 - Article

VL - 64

SP - S13-S17

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -